Age-related Macular Degeneration
Conditions
Keywords
Lucentis, AMD, Age-related macular degeneration, Subfoveal neovascular age-related macular degeneration, Wet AMD, Macular degeneration, Ranibizumab
Brief summary
This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Results are presented for the first 12 months of the study.
Interventions
DRUGRanibizumab
Sterile solution for intravitreal injection.
Sponsors
Genentech, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* For sexually active women of childbearing potential, agreement to the use of an appropriate form of contraception (or abstinence) for the duration of the study. Ocular Inclusion Criteria (Study Eye) * Best corrected visual acuity (BCVA), using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, of 20/40-20/320 (Snellen equivalent). * Choroidal neovascularization (CNV) lesions with classic CNV component, occult CNV, or with some classic CNV component were permissible. * Total area of lesion \< 12 disc area or 30.48 mm\^2.
Exclusion criteria
* History of vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD) in the study eye. * Prior treatment with Visudyne(R), external-beam radiation therapy, or transpupillary thermotherapy (TTT) in the study eye. * Previous intravitreal drug delivery (eg, intravitreal corticosteroid injection, anti-angiogenic drugs, or device implantation) in the study eye. * Previous treatment or participation in a clinical trial involving anti-angiogenic drugs (Avastin(R), anecortave acetate, protein kinase C inhibitors, etc), in the non-study eye within 3 months of Day 0 (first day of treatment). The patient may not have received Lucentis(R) or Macugen(R) in the non-study eye within 7 days of Day 0. * Treatment with Visudyne(R) in the non-study eye \< 7 days preceding Day 0. * Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either \> 50% of the total area of the lesion or \> 1 disc area (2.54 mm\^2) in size. * Subfoveal fibrosis or atrophy in the study eye. * CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia. * Retinal pigment epithelial tear involving the macula in the study eye. * Any concurrent intraocular condition in the study eye (eg, cataract or diabetic retinopathy) that, in the opinion of the investigator, could either: Require medical or surgical intervention during the 24-month study period to prevent or treat visual loss that might result from that condition; or if allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity (BCVA) over the 24-month study period. * Uncontrolled blood pressure. * Atrial fibrillation not managed by patient's primary care physician or cardiologist within 3 months of screening visit. * History of stroke within the last 3 months of screening visit. * History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications. * Current treatment for active systemic infection. * Active malignancy. * History of allergy to fluorescein, not amenable to treatment. * Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 | Baseline to Month 12 | BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12 | Baseline to Month 12 | BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. |
| Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12 | Month 12 | VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 is 14 lines correctly read in the EDTRS chart. |
| Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12 | Month 12 | The presence of fluid from choroidal neovascularization (CNV) was assessed by spectral domain optical coherence tomography (SD-OCT). No evidence of fluid was defined as no subretinal fluid thickness, no cystoid spaces, no intraretinal fluid, no pigment epithelial defect thickness, and average central subfield thickness \< 270 µm. |
| Number of Ranibizumab Injections up to But Not Including Month 12 | Baseline to Month 12 | — |
| Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Macular volume was assessed by spectral domain optical coherence tomography (SD-OCT). |
| Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12 | Baseline to Month 12 | The total area of choroidal neovascularization (CNV) and choroidal neovascular leakage was assessed with fluorescein angiography (FA). Area was measured in disc area units; 1 disc area unit = 2.54 mm\^2. |
| Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Central foveal thickness was assessed by spectral domain optical coherence tomography (SD-OCT). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ranibizumab 0.5 mg Monthly Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months. | 275 |
| Ranibizumab 2.0 mg Monthly Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months. | 274 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally. | 275 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally. | 273 |
| Total | 1,097 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 2 | 0 | 2 | 0 |
| Overall Study | Death | 8 | 5 | 4 | 5 |
| Overall Study | Lost to Follow-up | 2 | 2 | 2 | 2 |
| Overall Study | Patient's decision to withdraw | 4 | 9 | 4 | 8 |
| Overall Study | Physician's decision to withdraw patient | 1 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Total |
|---|---|---|---|---|---|
| Age Continuous | 78.8 years STANDARD_DEVIATION 8.4 | 79.3 years STANDARD_DEVIATION 8.3 | 78.5 years STANDARD_DEVIATION 8.3 | 78.3 years STANDARD_DEVIATION 8.3 | 78.7 years STANDARD_DEVIATION 8.3 |
| Sex: Female, Male Female | 162 Participants | 170 Participants | 163 Participants | 156 Participants | 651 Participants |
| Sex: Female, Male Male | 113 Participants | 104 Participants | 112 Participants | 117 Participants | 446 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 240 / 274 | 243 / 274 | 250 / 275 | 239 / 272 |
| serious Total, serious adverse events | 66 / 274 | 54 / 274 | 57 / 275 | 54 / 272 |
Outcome results
Primary
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement.
Time frame: Baseline to Month 12
Population: Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 | 10.1 Letters | Standard Deviation 13.3 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 | 9.2 Letters | Standard Deviation 14.6 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 | 8.2 Letters | Standard Deviation 13.3 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 | 8.6 Letters | Standard Deviation 13.8 |
Secondary
Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Central foveal thickness was assessed by spectral domain optical coherence tomography (SD-OCT).
Time frame: Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Population: Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Day 7 | -104.9 µm | Standard Deviation 130.3 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 1 | -141.5 µm | Standard Deviation 137.5 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 2 | -152.5 µm | Standard Deviation 142.4 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 3 | -157.0 µm | Standard Deviation 143.8 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 4 | -164.0 µm | Standard Deviation 146.6 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 6 | -162.0 µm | Standard Deviation 150 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 9 | -164.5 µm | Standard Deviation 151.8 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 12 | -172.0 µm | Standard Deviation 150.5 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 6 | -149.2 µm | Standard Deviation 144 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 4 | -151.8 µm | Standard Deviation 143.3 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 1 | -128.6 µm | Standard Deviation 133.3 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 12 | -163.3 µm | Standard Deviation 142.6 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 9 | -153.1 µm | Standard Deviation 144.8 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 3 | -147.9 µm | Standard Deviation 134.3 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 2 | -140.3 µm | Standard Deviation 131.1 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Day 7 | -84.9 µm | Standard Deviation 111.3 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 9 | -153.5 µm | Standard Deviation 147.1 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 2 | -142.9 µm | Standard Deviation 141.6 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 3 | -154.5 µm | Standard Deviation 147.9 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 4 | -142.7 µm | Standard Deviation 153.6 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 6 | -147.5 µm | Standard Deviation 151.9 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 12 | -161.2 µm | Standard Deviation 152.3 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Day 7 | -103.5 µm | Standard Deviation 141.3 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 1 | -132.6 µm | Standard Deviation 148.2 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 2 | -156.9 µm | Standard Deviation 145 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 3 | -164.9 µm | Standard Deviation 144.5 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 1 | -146.0 µm | Standard Deviation 144.3 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Day 7 | -100.6 µm | Standard Deviation 123.4 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 4 | -159.7 µm | Standard Deviation 148.8 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 12 | -172.4 µm | Standard Deviation 148.6 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 9 | -157.8 µm | Standard Deviation 155.6 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 6 | -159.1 µm | Standard Deviation 149.6 |
Secondary
Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Macular volume was assessed by spectral domain optical coherence tomography (SD-OCT).
Time frame: Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Population: Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Day 7 | -0.79 mm^3 | Standard Deviation 0.8 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 1 | -1.26 mm^3 | Standard Deviation 1.06 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 2 | -1.34 mm^3 | Standard Deviation 1.17 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 3 | -1.42 mm^3 | Standard Deviation 1.25 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 4 | -1.42 mm^3 | Standard Deviation 1.22 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 6 | -1.47 mm^3 | Standard Deviation 1.25 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 9 | -1.55 mm^3 | Standard Deviation 1.41 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 12 | -1.54 mm^3 | Standard Deviation 1.31 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 6 | -1.61 mm^3 | Standard Deviation 1.34 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 4 | -1.56 mm^3 | Standard Deviation 1.31 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 1 | -1.30 mm^3 | Standard Deviation 1.15 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 12 | -1.66 mm^3 | Standard Deviation 1.37 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 9 | -1.67 mm^3 | Standard Deviation 1.34 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 3 | -1.51 mm^3 | Standard Deviation 1.32 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 2 | -1.49 mm^3 | Standard Deviation 1.31 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Day 7 | -0.80 mm^3 | Standard Deviation 0.76 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 9 | -1.35 mm^3 | Standard Deviation 1.31 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 2 | -1.30 mm^3 | Standard Deviation 1.13 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 3 | -1.43 mm^3 | Standard Deviation 1.33 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 4 | -1.31 mm^3 | Standard Deviation 1.24 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 6 | -1.35 mm^3 | Standard Deviation 1.33 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 12 | -1.41 mm^3 | Standard Deviation 1.36 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Day 7 | -0.72 mm^3 | Standard Deviation 0.87 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 1 | -1.16 mm^3 | Standard Deviation 1.03 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 2 | -1.47 mm^3 | Standard Deviation 1.25 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 3 | -1.55 mm^3 | Standard Deviation 1.28 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 1 | -1.38 mm^3 | Standard Deviation 1.18 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Day 7 | -0.81 mm^3 | Standard Deviation 0.76 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 4 | -1.48 mm^3 | Standard Deviation 1.27 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 12 | -1.49 mm^3 | Standard Deviation 1.35 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 9 | -1.48 mm^3 | Standard Deviation 1.33 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12 | Month 6 | -1.48 mm^3 | Standard Deviation 1.36 |
Secondary
Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12
The total area of choroidal neovascularization (CNV) and choroidal neovascular leakage was assessed with fluorescein angiography (FA). Area was measured in disc area units; 1 disc area unit = 2.54 mm\^2.
Time frame: Baseline to Month 12
Population: Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ranibizumab 0.5 mg Monthly | Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12 | Change in the total area of CNV | -2.14 Disc area units | Standard Deviation 2.4 |
| Ranibizumab 0.5 mg Monthly | Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12 | Change in the total area of CNV leakage | -2.35 Disc area units | Standard Deviation 2.39 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12 | Change in the total area of CNV leakage | -2.63 Disc area units | Standard Deviation 2.34 |
| Ranibizumab 2.0 mg Monthly | Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12 | Change in the total area of CNV | -2.42 Disc area units | Standard Deviation 2.38 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12 | Change in the total area of CNV | -1.74 Disc area units | Standard Deviation 2.22 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12 | Change in the total area of CNV leakage | -2.01 Disc area units | Standard Deviation 2.28 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12 | Change in the total area of CNV | -1.98 Disc area units | Standard Deviation 2.39 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12 | Change in the total area of CNV leakage | -2.22 Disc area units | Standard Deviation 2.48 |
Secondary
Number of Ranibizumab Injections up to But Not Including Month 12
Time frame: Baseline to Month 12
Population: All treated patients. Observed data were used with no imputation.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ranibizumab 0.5 mg Monthly | Number of Ranibizumab Injections up to But Not Including Month 12 | 11.3 Injections | Standard Deviation 1.8 |
| Ranibizumab 2.0 mg Monthly | Number of Ranibizumab Injections up to But Not Including Month 12 | 11.2 Injections | Standard Deviation 2.1 |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Number of Ranibizumab Injections up to But Not Including Month 12 | 7.7 Injections | Standard Deviation 2.7 |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Number of Ranibizumab Injections up to But Not Including Month 12 | 6.9 Injections | Standard Deviation 2.4 |
Secondary
Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
Time frame: Baseline to Month 12
Population: Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ranibizumab 0.5 mg Monthly | Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12 | 34.5 Percentage of patients |
| Ranibizumab 2.0 mg Monthly | Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12 | 36.1 Percentage of patients |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12 | 30.2 Percentage of patients |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12 | 33.0 Percentage of patients |
Secondary
Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12
VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 is 14 lines correctly read in the EDTRS chart.
Time frame: Month 12
Population: Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ranibizumab 0.5 mg Monthly | Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12 | 52.4 Percentage of patients |
| Ranibizumab 2.0 mg Monthly | Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12 | 50.0 Percentage of patients |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12 | 46.2 Percentage of patients |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12 | 43.6 Percentage of patients |
Secondary
Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12
The presence of fluid from choroidal neovascularization (CNV) was assessed by spectral domain optical coherence tomography (SD-OCT). No evidence of fluid was defined as no subretinal fluid thickness, no cystoid spaces, no intraretinal fluid, no pigment epithelial defect thickness, and average central subfield thickness \< 270 µm.
Time frame: Month 12
Population: Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ranibizumab 0.5 mg Monthly | Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12 | 5.1 Percentage of patients |
| Ranibizumab 2.0 mg Monthly | Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12 | 5.8 Percentage of patients |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12 | 2.9 Percentage of patients |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12 | 4.8 Percentage of patients |